n 2009, CICS was launched at Brigham and Women's Hospital (BWH) in collaboration with Kowa Company Ltd, a Japanese corporation.

Since the late 1990ies research efforts in our laboratory have been focused on the understanding of the functions of the Collagen Triple Helix Repeat Containing-1 (Cthrc1), a molecule discovered in our laboratory in 1999 in the adventitia of injured arteries.

Endothelial cell Biology and hereditary hemorrhagic telangiectasia (HHT)

Our lab focuses on ligand receptor interactions that promote cellular and tissue injury.

The Pulmonary Hypertension Research Group is a collaboration of clinicians and researchers working together to reveal the pathogenesis of PH, identify the mechanisms of the disease, and develop new therapeutic approaches in order to improve the care of patients with PH.

Identification of pro and anti-inflammatory mechanisms in the vessel wall. Induction of the Th2 anti-inflammatory phenotype by resident vascular cells. Angiogenic mechanisms of anti-inflammatory interleukins.